

RealRate

PHARMACEUTICAL 2018

TENAX THERAPEUTICS INC. Rank 13 of 342







RealRate

PHARMACEUTICAL 2018

TENAX THERAPEUTICS INC. Rank 13 of 342

The relative strengths and weaknesses of TENAX THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TENAX THERAPEUTICS INC. compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 162% points. The greatest weakness of TENAX THERAPEUTICS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 235% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	8,063
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,009
Liabilities, Non-Current	0
Other Assets	1,818
Other Compr. Net Income	17,677
Other Expenses	0
Other Liabilities	0
Other Net Income	366
Other Revenues	0
Property and Equipment	9.9
Research and Development	3,527
Selling, General and Administrative Expense	5,679

Output Variable	Value in 1000 USD
Assets	9,891
Liabilities	1,009
Expenses	9,206
Revenues	0
Stockholders Equity	8,882
Net Income	-8,840
Comprehensive Net Income	-1.3
Economic Capital Ratio	280%

